Who are ANAVEX2-73 oral liquid's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): QUINIDINE, diphenhydramine/phenylephrine/cocoa; placebo; dextromethorphan, Dextromethorphan HBr, AXS-05, Dextromethorphan Oral Solution, Dextromethorphan hydrobromide with guaifenesin.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/anavex2-73-oral-liquid.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

ANAVEX2-73 oral liquid — Competitive Intelligence Brief

ANAVEX2-73 oral liquid (ANAVEX2-73 oral liquid) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: sigma-1 receptor agonist. Area: Neurology.

phase 2 sigma-1 receptor agonist sigma-1 receptor Neurology Small molecule Live · refreshed every 30 min

Target snapshot

ANAVEX2-73 oral liquid (ANAVEX2-73 oral liquid) — Anavex Life Sciences Corp.. ANAVEX2-73 is an oral liquid formulation of a sigma-1 receptor agonist.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
ANAVEX2-73 oral liquid TARGET	ANAVEX2-73 oral liquid	Anavex Life Sciences Corp.	phase 2	sigma-1 receptor agonist	sigma-1 receptor
QUINIDINE	QUINIDINE		marketed		sigma-1 receptor, NMDA receptor, CYP2D6	1950-01-01
diphenhydramine/phenylephrine/cocoa; placebo; dextromethorphan	diphenhydramine/phenylephrine/cocoa; placebo; dextromethorphan	Montefiore Medical Center	marketed	Combination cold/cough/allergy remedy	H1 histamine receptor (diphenhydramine); alpha-1 adrenergic receptor (phenylephrine); NMDA receptor and sigma-1 receptor (dextromethorphan)
Dextromethorphan HBr	Dextromethorphan HBr	Galera Therapeutics, Inc.	marketed	NMDA receptor antagonist; sigma-1 receptor agonist	NMDA receptor; sigma-1 receptor
AXS-05	AXS-05	Axsome Therapeutics, Inc.	marketed	Combination antidepressant (NMDA antagonist + norepinephrine-dopamine reuptake inhibitor)	Sigma-1 receptor, NMDA receptor, norepinephrine transporter, dopamine transporter
Dextromethorphan Oral Solution	Dextromethorphan Oral Solution	Helsinki University Central Hospital	marketed	Non-opioid antitussive	NMDA receptor antagonist; sigma-1 receptor
Dextromethorphan hydrobromide with guaifenesin	Dextromethorphan hydrobromide with guaifenesin	Washington University School of Medicine	marketed	Antitussive/expectorant combination	Sigma-1 receptor, NMDA receptor (dextromethorphan); non-specific expectorant mechanism (guaifenesin)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (sigma-1 receptor agonist class)

Anavex Life Sciences Corp. · 1 drug in this class
Durect · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). ANAVEX2-73 oral liquid — Competitive Intelligence Brief. https://druglandscape.com/ci/anavex2-73-oral-liquid. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab